Chronic Illness | Novartis

Media Release
Oct 29, 2024
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
Media Release
Oct 24, 2024
Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
Media Release
Sep 18, 2024
New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients
Media Release
Sep 17, 2024
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Media Release
May 31, 2024
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
Media Release
Mar 04, 2024
Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA
Media Release
Nov 09, 2023
Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2
Media Release
Oct 31, 2023
FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade
Media Release
Aug 09, 2023
Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticaria
Interior Page
Immunology
Story
Apr 07, 2022
Tackling the health toll of climate change
Media Release
Nov 08, 2021
Novartis presents positive Phase III results for Cosentyx® in children with active enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) at ACR 2021